Chronic Kidney Disease

Some consider patients with type 2 diabetes (T2D) and chronic kidney disease poor candidates for metformin monotherapy due to the risk of lactic acidosis. However, new research finds patients who can tolerate the drug can gain similar benefits with or without kidney disease.

Closing out the discussion, an expert in chronic kidney disease (CKD) highlights how care for patients with CKD may change in the future based on data presented at AMCP.

Robert Toto, MD, provides his expert opinion regarding recent data from Forsythe, et al about the clinical and humanistic burden of IgA nephropathy.

An expert in chronic kidney disease (CKD) provides a recap of data, recently released at AMCP, around the estimate of the US incident population of IgA nephropathy.

The new analysis suggests that dementia screenings might also include kidney function estimation.

An overview of the implications of the recent dapagliflozin data in chronic kidney disease (CKD) treatment to US clinicians and payers.

An expert in chronic kidney disease (CKD) discusses the importance of showing data at the 3-year mark for the DAPA-CKD study, released at AMCP.

Robert Toto, MD, recaps another recent analysis of data from DAPA-CKD that looked at the time-to-event and cost consequence of delaying clinical events in chronic kidney disease (CKD).

Two-thirds of patients with diabetic kidney disease who are eligible for treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors are not being prescribed them, a new study shows.

Sodium-glucose transporter 2 (SGLT2) inhibitors decrease the risk of acute kidney injury and severe hypoglycemia for those with diabetes, heart failure, and chronic kidney disease (CKD) but increase the risk of diabetic ketoacidosis.

A recap of the dapagliflozin data from the DAPA-CKD study and how it relates to reductions in healthcare resource utilization.

An expert in chronic kidney disease (CKD) provides an overview of healthcare resource utilization data from the DAPA-CKD study, which was recently released at AMCP.

Robert Toto, MD, discusses key factors of healthcare resource utilization for patients with chronic kidney disease (CKD) and gives an overview of the link between CKD and cardiovascular disease.

A report using data from the DAPA-CKD study found that dapagliflozin would lead to more than $99 million in savings in a population matched to the trial’s inclusion criteria.

The study results were released as nephrologists and others are awaiting the findings of a joint task force of 2 national kidney organizations looking at alternative approaches to estimating glomerular filtration rate.

Although the Center for Medicare and Medicaid Innovation (CMMI) has delayed the start of payment models for kidney care, one dialysis provider says it remains committed to the concept.

Last year, a data monitoring committee halted the DAPA-CKD trial when it found the evidence of efficacy was overwhelming, after it was shown the trial met all its primary and secondary end points for patients with chronic kidney disease, with and without type 2 diabetes.

New research highlights a relationship between chronic kidney disease (CKD) and cerebral small vessel disease.

Quality of life is similar between patients with chronic kidney disease (CKD) undergoing hemodialysis and those having continuous ambulatory peritoneal dialysis (CAPD) in the hospital.

Study results indicate a possible relationship between diabetic kidney disease (DKD) and frailty and risk of subsequent delirium and cognitive impairment.

The findings illustrate the importance of prioritizing COVID-19 vaccinations for patients on dialysis.

Anemia, which occurs in over 50% of patients with end-stage kidney disease, should not be considered an obstacle to home dialysis, according to a new report.

The announcement allowing the administration of COVID-19 vaccines in dialysis centers is part of a larger $10 billion investment, largely funded by the American Rescue Plan, to expand access.

Patient data about emergency department use by this population is limited, the authors said.

Improved understanding of the early mechanisms of chronic kidney disease (CKD) may be the next step in efforts to delay or reverse disease progression.